-
A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters
- Back
Metadata
Document Title
A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters
Author
Frantz P.N.,Barinov A.,Ruffié C.,Combredet C.,Najburg V.,de Melo G.D.,Larrous F.,Kergoat L.,Teeravechyan S.,Jongkaewwattana A.,Billon-Denis E.,Tournier J.-N.,Prot M.,Levillayer L.,Conquet L.,Montagutelli X.,Tichit M.,Hardy D.,Fernandes P.,Strick-Marchand H.,Di Santo J.,Simon-Lorière E.,Bourhy H.,Tangy F.
Name from Authors Collection
Affiliations
Institut Pasteur, Université de Paris, Innovation Lab: Vaccines, Paris, France; National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency, Virology and Cell Technology Laboratory, Pathumthani, Thailand; Viroxis, Paris, France; Institut Pasteur, Université de Paris, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France; Armed Forces Biomedical Research Institute (IRBA), Microbiology and infectious diseases department, Brétgny-sur-Orge, France; Institut Pasteur, Université de Paris, Evolutionary Genomics of RNA viruses unit, Paris, France; Institut Pasteur, Université de Paris, Laboratory of Mouse Genetics, Paris, France; Institut Pasteur, Université de Paris, Experimental Neuropathology unit, Paris, France; Institut Pasteur, Université de Paris, INSERM U1223, Innate Immunity unit, Paris, France
Type
Article
Source Title
Nature Communications
ISSN
20411723
Year
2021
Volume
12
Issue
1
Open Access
All Open Access, Gold, Green
Publisher
Nature Research
DOI
10.1038/s41467-021-26506-2
Abstract
Several COVID-19 vaccines have now been deployed to tackle the SARS-CoV-2 pandemic, most of them based on messenger RNA or adenovirus vectors.The duration of protection afforded by these vaccines is unknown, as well as their capacity to protect from emerging new variants. To provide sufficient coverage for the world population, additional strategies need to be tested. The live pediatric measles vaccine (MV) is an attractive approach, given its extensive safety and efficacy history, along with its established large-scale manufacturing capacity. We develop an MV-based SARS-CoV-2 vaccine expressing the prefusion-stabilized, membrane-anchored full-length S antigen, which proves to be efficient at eliciting strong Th1-dominant T-cell responses and high neutralizing antibody titers. In both mouse and golden Syrian hamster models, these responses protect the animals from intranasal infectious challenge. Additionally, the elicited antibodies efficiently neutralize in vitro the three currently circulating variants of SARS-CoV-2. © 2021, The Author(s).
Industrial Classification
Knowledge Taxonomy Level 1
Knowledge Taxonomy Level 2
Knowledge Taxonomy Level 3
Funding Sponsor
Coalition for Epidemic Preparedness Innovations
License
CC BY
Rights
Publisher
Publication Source
Scopus